Dr Afsar Mian
Dr Afsar Ali Mian got his Master of Philosophy (MPhil) in Molecular Biology from Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan in 2003. After completion of MPhil he was awarded a scholarship under German Exchange Program (DAAD) in the Department of Pharmaceutical Biology, Julius-von-Sachs-Institute for Biosciences, University of Würrzburg, Germany. He completed his PhD from the Department of Hematology and Oncology, School of Medicines, Goethe University Frankfurt am Main, Germany in 2010 under the supervision of PD Dr. Martin Ruthardt. He then continued his research in the same laboratory as a postdoctoral fellow and focused on molecular targeting and resistance mechanisms in Philadelphia chromosome-positive leukemia till 2015. In 2015, Dr Mian joined Professor Dr Oliver Ottmann laboratory in the Department of Hematology, Division of Cancer and Genetics, School of Medicines, Cardiff University as a research fellow.
Dr Mian supervised two PhD, and several MD and bachelor students. He has been scientific journal reviewer of many journals like BMC Cancer, Biotechnology and Applied Biochemistry, Genetic Vaccines and Therapy, Infection, Genetics and Evolution, and Virology Journal.
Dr Mian has led the development of novel drugs and highly targeted approaches, including peptide therapies and molecularly directed agents against leukemia. His research efforts have been focused on providing therapy for patients suffering from treatment-resistant or refractory leukemia, with a special emphasis on acute lymphoblastic leukemia and on interrogating the mechanisms of resistance to targeted therapy. He has published his work in peer-reviewed journals focused on hematology developmental therapeutics and has particular interests in developing national and international collaborations across the bioscience spectrum and leading pharmaceutical industry.
Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, . . . Ruthardt M (2015). PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia, 29(5), 1104-1114. doi:10.1038/leu.2014.326. Link
Mian AA, Oancea C, Zhao Z, Ottmann OG and Ruthardt M (2009). Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia, 23(12), 2242-2247. doi:10.1038/leu.2009.194. Link
Mian AA, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, . . . Ruthardt M (2009). The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia, 23(9), 1614-1621. doi:10.1038/leu.2009.69. Link
Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, and Ruthardt M (2012). p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica, 97(2), 251-257. doi:10.3324/haematol.2011.047191. Link